Apollo Hospitals group has recently unveiled the ZAP-X gyroscopic radiosurgery platform, a groundbreaking technology aimed at treating brain tumors. This marks a significant milestone as it becomes the first facility in South Asia to adopt this state-of-the-art technology. ZAP-X, a computer-controlled machine, precisely delivers radiation to target areas within the brain.

This new technology, ZAP-X, promises to revolutionize brain tumor treatment by offering patients a non-invasive and pain-free alternative. Treatment sessions are remarkably brief, lasting only 30 minutes. According to a statement from the Chennai-based healthcare giant, ZAP-X sets a new standard for precision while minimizing radiation exposure. Unlike conventional methods, ZAP-X employs a self-shielded, gyroscopic linear accelerator design to precisely focus radiation beams from numerous angles onto the targeted tumor or area.

The innovative features of ZAP-X enhance patient outcomes by reducing exposure to critical structures such as the brain stem, eyes, and optic nerves. This, in turn, minimizes damage to healthy brain tissue and preserves cognitive function, ensuring a higher quality of life post-treatment.

ZAP-X's clinical capabilities extend to treating various brain conditions, including primary and metastatic brain tumors, arteriovenous malformations (AVMs), trigeminal neuralgia, movement disorders like Parkinson's disease, epilepsy, and other intracranial lesions such as meningiomas, acoustic neuromas, and pituitary adenomas. The technology promises greater accuracy and fewer side effects for patients.

Prathap Chandra Reddy, the founder chairman of Apollo Hospitals Group, expressed enthusiasm about the introduction of ZAP-X, emphasizing its non-invasive nature, minimal radiation exposure, and advanced safety protocols. He highlighted the technology's potential to improve accessibility and convenience for patients, aiming to make it available across the country and beyond.

ZAP-X offers several key advantages, including its non-invasive approach, pain-free treatment, frameless design for pinpoint accuracy, and real-time image guidance, resulting in shorter treatment durations and enhanced patient safety. With an impressive success rate, ZAP-X ensures effective control and relief for various conditions with minimal side effects.

John R. Adler, Founder and CEO of Zap Surgical and Professor of Neurosurgery at Stanford School of Medicine, hailed stereotactic radiosurgery as one of the most significant medical advancements of the past century. He emphasized that ZAP-X enables eligible patients to receive quick treatment in an outpatient setting without the need for surgical resections or whole-brain radiotherapy.

Traditional brain surgeries typically last 3-4 hours, whereas ZAP-X completes treatment within a single session lasting no more than 30 minutes. This allows for a day-care procedure, enabling patients to return home post-treatment without the need for prolonged hospitalization or anesthesia.

With a team of over 300 neurosurgeons and neurologists, Apollo Hospitals annually treats more than 25,000 patients, performing nearly 6,000 brain and spinal surgeries. The introduction of ZAP-X marks a significant advancement in the hospital's commitment to providing innovative and effective healthcare solutions.

Scientists discovered how brain cells talk

Study finds Gold Nanoparticles Hold Remarkable Anti-Aging Potential in Health and Beauty